TY - JOUR
T1 - Patterns of prescription and adherence to European Association of Urology guidelines on androgen deprivation therapy in prostate cancer
T2 - An Italian multicentre cross-sectional analysis from the Choosing Treatment for Prostate Cancer (CHOICE) study
AU - Morgia, Giuseppe
AU - Russo, Giorgio Ivan
AU - Tubaro, Andrea
AU - Bortolus, Roberto
AU - Randone, Donato
AU - Gabriele, Pietro
AU - Trippa, Fabio
AU - Zattoni, Filiberto
AU - Porena, Massimo
AU - Mirone, Vincenzo
AU - Serni, Sergio
AU - Del Nero, Alberto
AU - Lay, Giancarlo
AU - Ricardi, Umberto
AU - Rocco, Francesco
AU - Terrone, Carlo
AU - Pagliarulo, A.
AU - Ludovico, Giuseppe
AU - Vespasiani, G.
AU - Brausi, M.
AU - Simeone, Claudio
AU - Novella, Giovanni
AU - Carmignani, Giorgio
AU - Leonardi, Rosario
AU - Pinnarò, Paola
AU - De Paula, Ugo
AU - Corvo, Renzo
AU - Tenaglia, R.
AU - Siracusano, S.
AU - Mantini, Giovanna
AU - Gontero, P.
AU - Savoca, Gianfranco
AU - Ficarra, Vincenzo
PY - 2016
Y1 - 2016
N2 - Objective: To evaluate both the patterns of prescription of androgen deprivation therapy (ADT) in patients with prostate cancer (PCa) and the adherence to European Association of Urology (EAU) guidelines for ADT prescription. Methods: The Choosing Treatment for Prostate Cancer (CHOICE) study was an Italian multicentre cross-sectional study conducted between December 2010 and January 2012. A total of 1 386 patients, treated with ADT for PCa (first prescription or renewal of ADT), were selected. With regard to the EAU guidelines on ADT, the cohort was categorized into discordant ADT (Group A) and concordant ADT (Group B). Results: The final cohort included 1 075 patients with a geographical distribution including North Italy (n = 627, 58.3%), Central Italy (n = 233, 21.7%) and South Italy (n = 215, 20.0%). In the category of patients treated with primary ADT, a total of 125 patients (56.3%) were classified as low risk according to D'Amico classification. With regard to the EAU guidelines, 285 (26.51%) and 790 patients (73.49%) were classified as discordant (Group A) and concordant (Group B), respectively. In Group A, patients were more likely to receive primary ADT (57.5%, 164/285 patients) than radical prostatectomy (RP; 30.9%, 88/285 patients), radiation therapy (RT; 6.7%, 19/285 patients) or RP + RT (17.7%, 14/285 patients; P <0.01). Multivariate logistic regression analysis, adjusted for clinical and pathological variables, showed that patients from Central Italy (odds ratio [OR] 2.86; P <0.05) and South Italy (OR 2.65; P <0.05) were more likely to receive discordant ADT. Conclusion: EAU guideline adherence for ADT was low in Italy and was influenced by geographic area. Healthcare providers and urologists should consider these results in order to quantify the inadequate use of ADT and to set policy strategies to overcome this risk.
AB - Objective: To evaluate both the patterns of prescription of androgen deprivation therapy (ADT) in patients with prostate cancer (PCa) and the adherence to European Association of Urology (EAU) guidelines for ADT prescription. Methods: The Choosing Treatment for Prostate Cancer (CHOICE) study was an Italian multicentre cross-sectional study conducted between December 2010 and January 2012. A total of 1 386 patients, treated with ADT for PCa (first prescription or renewal of ADT), were selected. With regard to the EAU guidelines on ADT, the cohort was categorized into discordant ADT (Group A) and concordant ADT (Group B). Results: The final cohort included 1 075 patients with a geographical distribution including North Italy (n = 627, 58.3%), Central Italy (n = 233, 21.7%) and South Italy (n = 215, 20.0%). In the category of patients treated with primary ADT, a total of 125 patients (56.3%) were classified as low risk according to D'Amico classification. With regard to the EAU guidelines, 285 (26.51%) and 790 patients (73.49%) were classified as discordant (Group A) and concordant (Group B), respectively. In Group A, patients were more likely to receive primary ADT (57.5%, 164/285 patients) than radical prostatectomy (RP; 30.9%, 88/285 patients), radiation therapy (RT; 6.7%, 19/285 patients) or RP + RT (17.7%, 14/285 patients; P <0.01). Multivariate logistic regression analysis, adjusted for clinical and pathological variables, showed that patients from Central Italy (odds ratio [OR] 2.86; P <0.05) and South Italy (OR 2.65; P <0.05) were more likely to receive discordant ADT. Conclusion: EAU guideline adherence for ADT was low in Italy and was influenced by geographic area. Healthcare providers and urologists should consider these results in order to quantify the inadequate use of ADT and to set policy strategies to overcome this risk.
KW - Adherence
KW - Androgen deprivation therapy
KW - European Association of Urology
KW - Guidelines
KW - Prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=84953791276&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84953791276&partnerID=8YFLogxK
U2 - 10.1111/bju.13307
DO - 10.1111/bju.13307
M3 - Article
SN - 1464-4096
JO - BJU International
JF - BJU International
ER -